Alzheimer's disease is a major health problem with limited available medical treatment
options. Immunotherapy is one approach with the potential to slow or reverse the disease …

Many new therapeutics for Alzheimer's disease delay the accumulation of amyloid-β (Aβ) in
transgenic mice, but evidence for clearance of preexisting plaques is often lacking. Here, we …

Immunotherapeutic efforts to slow the clinical progression of Alzheimer's disease (AD) by
lowering brain amyloid-β (Aβ) have included Aβ vaccination, intravenous immunoglobulin …

Immunotherapy can attenuate amyloid neuropathology and improve cognitive function in
transgenic models of Alzheimer's disease. However, the first clinical trial was halted when …

Although extracellular Aβ plaques are a hallmark of Alzheimer's disease, it remains to be
determined whether extracellular or intracellular Aβ accumulation initiates the disease …

Amyloid-beta (Aβ) is suggested to play a causal role in the pathogenesis of Alzheimer's
disease (AD). Immunotherapies are among the most promising Aβ-targeting therapeutic …

Immunotherapy against beta-amyloid (Abeta) peptide in transgenic mouse models of
Alzheimer's disease alleviates the amyloid-associated pathology via three distinct …

There is substantial and compelling evidence that aggregation and accumulation of amyloid
β protein (Aβ) plays a pivotal role in the development of Alzheimer's disease (AD); thus …

Recent studies have demonstrated the potential utility of antibodies for the treatment of
Alzheimer's disease (AD). In transgenic mouse models of AD, peripheral and intracerebral …

The mechanisms by which anti-Aβ antibodies clear amyloid plaques in Aβ depositing
transgenic mice are unclear. In the current study, we demonstrate that inhibition of anti-Aβ …